The important announcements for Hong Kong stocks yesterday are as follows:

Operational data

$DONGFENG GROUP (00489.HK)$: The cumulative sales volume for the first 3 months was 522,100 units, an increase of about 14.8% over the previous year.

$COUNTRY GARDEN (02007.HK)$: Contract sales in March were 4.3 billion yuan, compared to 25 billion yuan in the same period last year.

$MIDEA REAL EST (03990.HK)$: In the first 3 months, cumulative contract sales were 10.39 billion yuan, a year-on-year decrease of 56.07%

$AGILE GROUP (03383.HK)$: In the first 3 months, cumulative contract sales were 5.36 billion yuan, with an average price of 14,201 yuan per square meter.

$KWG GROUP (01813.HK)$: In March, contract sales were 1.07 billion yuan, a year-on-year decrease of 72.2%.

$JINGRUI HLDGS (01862.HK)$: In the first 3 months, cumulative contract sales amounted to 488 million yuan, a year-on-year decrease of 60.58%.

Company news

$MEITUAN-W (03690.HK)$: Grant of 602.18 million bonus shares.

$CHINA OVERSEAS (00688.HK)$: Set up a project company with Shanghai Longhua Construction to invest in the development of related project plots.

According to the announcement, the relevant plot is that CNOOC Enterprise Development and Shanghai Longhua Construction successfully jointly invested 85% and 15% of the land use rights for the project plot at a cost of RMB 24.016 billion on October 24, 2023.

$OCFT (06638.HK)$: Completed the sale of 100% shares in Ping An One Account Bank.

$TONGDAO LIEPIN (06100.HK)$: Subscribe to a structured deposit product of 230 million yuan.

$CHINA BLUECHEM (03983.HK)$: Subscribe to 400 million yuan structured deposit products.

$REMEGEN (09995.HK)$: The US Food and Drug Administration's fast track determination of tetracip for the treatment of primary dry syndrome.

$JUNSHI BIO (01877.HK)$: The marketing application for new indications of angorizumab injection was accepted, mainly for cholesterolemia.

$HEPALINK (09989.HK)$: Exarane was approved for sale by the Food and Drug Administration of Thailand.

$PHARMARON (03759.HK)$: The actual controller, Lou Xiaoqiang, deferred the repurchase of some of the pledged shares (427,500 pledged shares).

$BOYAA (00434.HK)$: It is proposed to invest 1 million US dollars to further promote the Group's business development and layout in the Web3 field.

Buyback News

$BABA-SW (09988.HK)$: In the first quarter, the company repurchased a total of 524 million shares of common stock at a total price of US$4.8 billion.

During the quarter ended March 31, 2024, a total of 524 million shares of common stock (equivalent to 65 million American Depositary Shares) were repurchased at a total price of US$4.8 billion. In the financial year ending March 31, 2024, a total of 1,249 billion common shares were repurchased at a total price of US$12.5 billion.

$TENCENT (00700.HK)$: Approximately HK$1 billion was spent to repurchase 3.23 million shares at a repurchase price of HK$308.2-311.2.

$HSBC HOLDINGS (00005.HK)$: HK$145 million was spent to repurchase 2,364,400 shares at a repurchase price of HK$61.00-61.55.

$CK ASSET (01113.HK)$: An amount of HK$26.9916 million was spent to repurchase 835,000 shares at a repurchase price of HK$32.25-32.35.

$CHINASOFT INT'L (00354.HK)$: It spent approximately HK$23.9241,000 to repurchase 5 million shares at a repurchase price of HK$4.57-4.85.

$SIMCERE PHARMA (02096.HK)$: 1.78 million shares were repurchased at HK$9.368,500, at a repurchase price of HK$5.20-HK$5.32.

Editor/jayden